[
    [
        {
            "time": "2018",
            "original_text": "华华东医药聘任李邦良为名誉董事长 2018年薪酬为220万元",
            "features": {
                "keywords": [
                    "华东医药",
                    "李邦良",
                    "名誉董事长",
                    "薪酬",
                    "220万元"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华华东医药聘任李邦良为名誉董事长 2018年薪酬为220万元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018",
            "original_text": "卸任董事长后，李邦良再被聘为华东医药名誉董事长",
            "features": {
                "keywords": [
                    "卸任",
                    "董事长",
                    "李邦良",
                    "华东医药",
                    "名誉董事长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "卸任董事长后，李邦良再被聘为华东医药名誉董事长",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药生物 | 改革阵痛期，寻找结构调整中的机遇",
            "features": {
                "keywords": [
                    "医药生物",
                    "改革",
                    "阵痛期",
                    "结构调整",
                    "机遇"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物 | 改革阵痛期，寻找结构调整中的机遇",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]